Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
McKesson
Mallinckrodt
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,982,283

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,982,283 protect, and when does it expire?

Patent 6,982,283 protects AMITIZA and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.

Summary for Patent: 6,982,283
Title:Method for treating drug-induced constipation
Abstract: Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/135,397
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,982,283
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,982,283

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes   Start Trial   Start Trial METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,982,283

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035237   Start Trial
Argentina 100696   Start Trial
Austria 355067   Start Trial
Australia 2002251554   Start Trial
Brazil 0209327   Start Trial
Canada 2444103   Start Trial
China 1522147   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.